Williams K, Flanagan A, Folpe A, Thakker R, Athanasou N A
Department of Pathology, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre University of Oxford, Oxford OX3 7LD, UK.
Virchows Arch. 2007 Nov;451(5):871-5. doi: 10.1007/s00428-007-0471-y. Epub 2007 Aug 3.
Oncogenic osteomalacia (OO) is an acquired form of hypophosphataemic osteomalacia, which is associated most commonly with the development of a benign phosphaturic mesenchymal tumour mixed connective tissue type (PMTMCT). PMTMCTs are generally well vascularised tumours, and many have in the past been classified as haemangiomas and haemangiopericytomas. Although these tumours show some morphological variation, it has been proposed that they represent a distinct histopathological entity. Our aim in this study was to determine by immunohistochemistry the vascular profile of PMTMCT. Using monoclonal antibodies directed against several vascular markers, including the lymphatic endothelial cell antigens LYVE 1 and podoplanin, we found that PMTMCTs, in contrast to haemangiomas and haemangiopericytomas, contain lymphatic vessels. Taken with previous observations that PMTMCTs overexpress FGF23 and other gene products, this finding provides further evidence that most osteomalacia associated mesenchymal tumours represent a discrete pathological entity.
致癌性骨软化症(OO)是一种获得性低磷性骨软化症,最常与良性混合型磷酸尿性间叶肿瘤(PMTMCT)的发生相关。PMTMCT通常是血管丰富的肿瘤,过去许多被归类为血管瘤和血管外皮细胞瘤。尽管这些肿瘤表现出一些形态学差异,但有人提出它们代表一种独特的组织病理学实体。本研究的目的是通过免疫组织化学确定PMTMCT的血管特征。使用针对几种血管标志物的单克隆抗体,包括淋巴管内皮细胞抗原LYVE 1和足板蛋白,我们发现与血管瘤和血管外皮细胞瘤不同,PMTMCT含有淋巴管。结合之前关于PMTMCT过度表达FGF23和其他基因产物的观察结果,这一发现进一步证明,大多数与骨软化症相关的间叶肿瘤代表一种离散的病理实体。